Andreas Wassmer
YOU?
Author Swipe
View article: Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence
Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence Open
People living with sickle cell disease (SCD) face intermittent acute pain episodes due to vaso-occlusion primarily treated palliatively with opioids. Hemolysis of sickle erythrocytes promotes release of heme, which activates inflammatory c…
View article: Heme-stress activated NRF2 skews fate trajectories of bone marrow cells from dendritic cells towards red pulp-like macrophages in hemolytic anemia
Heme-stress activated NRF2 skews fate trajectories of bone marrow cells from dendritic cells towards red pulp-like macrophages in hemolytic anemia Open
View article: Hemopexin dosing improves cardiopulmonary dysfunction in murine sickle cell disease
Hemopexin dosing improves cardiopulmonary dysfunction in murine sickle cell disease Open
View article: Modular Platform for the Development of Recombinant Hemoglobin Scavenger Biotherapeutics
Modular Platform for the Development of Recombinant Hemoglobin Scavenger Biotherapeutics Open
Cell-free hemoglobin (Hb) is a driver of disease progression in conditions with intravascular or localized hemolysis. Genetic and acquired anemias or emergency medical conditions such as aneurysmal subarachnoid hemorrhage involve tissue Hb…
View article: Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation
Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation Open
Hemopexin is the main plasmatic scavenger of cell-free heme, released in the context of intravascular hemolysis or major cell injury. Heme is indispensable for the oxygen transport by hemoglobin but when released outside of the erythrocyte…